Incyte Corp
INCYHealthcare|Biotechnology|USA
$93.59
-1.27 (-1.34%)
DCF (FCF)
$55.64
Tangible Book
$24.78
Graham Number
$61.53
Earnings Power
$50.38
Clinical Trials (478)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04680052 A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. | Follicular Lymphoma, Marginal Zone Lymphoma | P3 | Active | 654 | RCT, Double-blind | tafasitamab, rituximab, lenalidomide, placebo |
| NCT06804811 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | NonSegmental Vitiligo | P3 | Recruiting | 250 | RCT, Double-blind | Ruxolitinib Cream, Vehicle Cream |
| NCT06113471 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | NonSegmental Vitiligo | P3 | Active | 450 | RCT, Double-blind | Povorcitinib, Placebo |
| NCT06821542 A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy | Chronic Graft-versus-host-disease | P3 | Active | 9 | RCT, Open-label | INCA034176, Best Available Therapy (BAT) |
| NCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | Diffuse Large B-cell Lymphoma | P3 | Active | 899 | RCT, Double-blind | Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo |
| NCT06212999 A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | P3 | Active | 617 | RCT, Double-blind | Povorcitinib |
| NCT04205812 Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer | P3 | Active | 583 | RCT, Double-blind | Retifanlimab, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel |
| NCT07284849 A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | CRC (Colorectal Cancer) | P3 | Recruiting | 700 | RCT, Double-blind | INCA33890, Placebo, Bevacizumab, FOLFOX |
| NCT06615050 A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) | Graft-versus-host Disease (GVHD) | P3 | Recruiting | 572 | RCT, Open-label | Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF) |
| NCT06263478 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease | Chronic Graft-versus-host-disease | P3 | Active | 21 | Open-label | INCA034176 |
| NCT06548360 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | NonSegmental Vitiligo | P3 | Recruiting | 180 | RCT, Double-blind | Ruxolitinib Cream, Vehicle Cream |
| NCT06113445 A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) | NonSegmental Vitiligo | P3 | Active | 467 | RCT, Double-blind | Povorcitinib, Placebo |
| NCT07214779 Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Ovarian Cancer | P3 | Recruiting | 466 | RCT, Open-label | INCB123667, Investigator's choice of chemotherapy |
| NCT05429268 Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) | Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma | P3 | Active | 82 | Open-label | Tafasitamab, Lenalidomide |
| NCT03952559 A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis | Atopic Dermatitis | P3 | Active | 516 | RCT, Double-blind | Baricitinib, Placebo, Topical corticosteroid |
| NCT06516952 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | Prurigo Nodularis | P3 | Recruiting | 330 | RCT, Double-blind | Povorcitinib, Placebo |
| NCT06516965 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | Prurigo Nodularis | P3 | Recruiting | 330 | RCT, Double-blind | Povorcitinib, Placebo |
| NCT03117751 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma | P2P3 | Active | 790 | RCT, Single-blind | Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol |
| NCT06958211 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | Hidradenitis Suppurativa | P3 | Recruiting | 550 | RCT, Double-blind | Ruxolitinib Cream, Vehicle Cream |
| NCT06959225 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | Hidradenitis Suppurativa | P3 | Recruiting | 550 | RCT, Double-blind | Ruxolitinib Cream, Vehicle Cream |
| NCT06855498 Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | Hidradenitis Suppurativa (HS) | P3 | Recruiting | 600 | Open-label | povorcitinib |
| NCT06585774 A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Chronic Graft-versus-host-disease | P3 | Recruiting | 240 | RCT, Double-blind | INCA034176, Placebo, Corticosteroids |
| NCT06832618 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis | Atopic Dermatitis | P3 | Recruiting | 240 | RCT, Double-blind | Ruxolitinib, Vehicle Cream |
| NCT04455841 INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders | Anemia, Post-essential Thrombocythemia Myelofibrosis | P1P2 | Active | 84 | Open-label | INCB000928, ruxolitinib |
| NCT04577014 Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma | Soft Tissue Sarcoma, Sarcoma,Soft Tissue | P1P2 | Recruiting | 98 | Open-label | Retifanlimab, Gemcitabine, Docetaxel |
| NCT04661007 To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) | Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma | P1P2 | Active | 72 | Open-label | tafasitamab, lenalidomide, parsaclisib, R-CHOP |
| NCT07104565 Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | Immune Thrombocytopenia | P2 | Recruiting | 56 | Open-label | INCA000585 |
| NCT03516708 Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer | Rectal Cancer | P1P2 | Recruiting | 49 | Open-label | Epacadostat, CAPOX chemotherapy, FOLFOX chemotherapy |
| NCT07228624 Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes | Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis | P2 | Recruiting | 50 | Open-label | Ruxolitinib, Busulfan, Cyclophosphamide, Fludarabine, JAK Inhibitor, Melphalan, Methotrexate, Tacrolimus |
| NCT06792825 HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL | Follicular Lymphoma, Marginal Zone Lymphoma | P2 | Recruiting | 65 | Open-label | Tafasitamab, Rituximab, Lenalidomide |
| NCT04160546 Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP) | Chronic Myeloid Leukemia, Chronic Phase | P2 | Active | 80 | Open-label | Ponatinib 15 MG, Acetylsalicylic acid 100 MG |
| NCT06906562 A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma | P2 | Recruiting | 40 | Open-label | Pemigatinib |
| NCT06320405 Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors | Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | P1P2 | Recruiting | 38 | Open-label | Axatilimab, Paclitaxel, Retifanlimab |
| NCT07219576 Retifanlimab and Ruxolitinib In Solid Malignancies | Non Small Cell Lung Carcinoma, Renal Cell Carcinoma | P1P2 | Recruiting | 40 | Open-label | Ruxolitinib, Retifanlimab |
| NCT04463771 Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | Endometrial Cancer | P2 | Active | 206 | Open-label | retifanlimab, epacadostat, pemigatinib, INCAGN02385, INCAGN02390 |
| NCT06728410 A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement | Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement | P2 | Recruiting | 38 | Open-label | Pemigatinib, Durvalumab |
| NCT04644211 Ruxolitinib in Thrombocythemia and Polycythemia Vera | Essential Thrombocythemia, Polycythemia Vera | P2 | Recruiting | 60 | Open-label | Ruxolitinib |
| NCT06760156 Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym | Large B-cell Lymphoma | P2 | Recruiting | 28 | Open-label | Tafasitamab, Lenalidomide |
| NCT06029309 Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma | Mantle Cell Lymphoma | P1P2 | Recruiting | 27 | Open-label | Zanubrutinib, Tafasitamab |
| NCT02876302 Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | Inflammatory Breast Cancer (IBC) | P2 | Active | 23 | RCT, Open-label | Ruxolitinib, Paclitaxel, Doxorubicin, Cyclophosphamide |
| NCT05723055 Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | Hodgkin Lymphoma | P2 | Recruiting | 9 | Open-label | Axatilimab, Nivolumab |
| NCT06465433 Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab | Hematologic Malignancies | P2 | Recruiting | 25 | Open-label | Tafasitamab |
| NCT06752694 Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia | Aplastic Anemia | P2 | Recruiting | 20 | Open-label | Cyclosporine, Fludarabine, Granulocyte Colony-Stimulating Factor, Mycophenolate Mofetil, Ruxolitinib, Sirolimus |
| NCT03801434 Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells | P2 | Recruiting | 10 | Open-label | Ruxolitinib |
| NCT06859424 A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation | AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL) | P2 | Recruiting | 358 | RCT, Open-label | Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Seizure prophylaxis, Supportive Care: Prophylaxis against infections |
| NCT06773195 A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis | Myelofibrosis | P1P2 | Recruiting | 37 | Open-label | Ulixertinib, Ruxolitinib |
| NCT05888844 A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | P2 | Active | 63 | RCT, Open-label | INCB099280 |
| NCT06300528 Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma | P2 | Recruiting | 27 | Open-label | Pemigatinib |
| NCT03414229 A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Sarcoma | P2 | Active | 30 | Open-label | Epacadostat, Pembrolizumab |
| NCT06843408 A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | Chronic Graft-versus-host-disease | P1P2 | Recruiting | 30 | Open-label | INCA034176 |
| NCT04551131 Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis | Hemophagocytic Lymphohistiocytosis | P1P2 | Active | 10 | Open-label | Ruxolitinib, Dexamethasone, Etoposide |
| NCT03722407 Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion | Chronic Myelomonocytic Leukemia, Leukemia | P2 | Active | 29 | Open-label | Ruxolitinib |
| NCT06439485 Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion | Advanced Cholangiocarcinoma, FGFR2 Fusion | P1P2 | Recruiting | 25 | Open-label | Pemigatinib, Atezolizumab, Bevacizumab |
| NCT06663722 Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease | Chronic Graft Versus Host Disease, cGVHD | P2 | Recruiting | 49 | Open-label | Axatilimab |
| NCT06653777 Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells | Solid Tumor, Miscellaneous | P2 | Recruiting | 40 | Open-label | Pemigatinib |
| NCT04445844 INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma | P2 | Active | 25 | Open-label | Pelareorep, Retifanlimab |
| NCT03681561 Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | Hodgkin Lymphoma | P1P2 | Recruiting | 54 | Open-label | Ruxolitinib, Nivolumab |
| NCT07011810 Axatilimab for Sclerotic Chronic Graft-versus-Host Disease | Chronic Graft Versus Host Disease | P2 | Recruiting | 50 | Open-label | Axatilimab |
| NCT05851443 A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Moderate to Severe Asthma | P2 | Recruiting | 240 | RCT, Double-blind | povorcitinib, ICS-LABA |
| NCT06660355 Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy | Chronic Graft-versus-host Disease (cGVHD) | P2 | Recruiting | 120 | RCT, Open-label | Ruxolitinib, Prednisone |
| NCT05583071 Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | Non-Hodgkin Lymphoma | P2 | Recruiting | 20 | Open-label | Tafasitamab, Lenalidomide, Rituximab, Methotrexate |
| NCT04509700 Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | B-Cell Malignancies | P2 | Active | 112 | Open-label | Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib, parsaclisib + ibrutinib |
| NCT03069326 A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | Myelofibrosis | P2 | Active | 30 | Open-label | Ruxolitinib, Thalidomide |
| NCT06991101 Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma | Glioblastoma, Brain Cancer | P2 | Recruiting | 190 | RCT, Open-label | Ruxolitinib, Temozolomide |
| NCT07249346 Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation | Leukemia, Myelodysplasia | P2 | Recruiting | 124 | Open-label | Ruxolitinib, Myeloablative conditioning regimen, Cyclophosphamide, Tacrolimus |
| NCT07283822 Amping up With PemJAK | Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma | P2 | Recruiting | 53 | Open-label | Ruxolitinib, Pembrolizumab |
| NCT05757219 Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | Diffuse Large B Cell Lymphoma | P2 | Recruiting | 27 | Open-label | Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy |
| NCT06345495 High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | Splenomegaly, Myelofibrosis | P2 | Recruiting | 30 | Open-label | Ruxolitinib, Levetiracetam, Eltrombopag, Busulfan, Romiplostim, Fludarabine phosphate, Cyclophosphamide, Mesna, Tacrolimus |
| NCT07128381 Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML) | P1P2 | Recruiting | 66 | Open-label | Axatilimab (SNDX-6352), Ruxolitinib |
| NCT02925234 The Drug Rediscovery Protocol (DRUP Trial) | Cancer, Tumors | P2 | Recruiting | 1,550 | Open-label | Panitumumab, Olaparib, Dabrafenib, Nilotinib, Trametinib, Erlotinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib, Regorafenib, Nivolumab, Afatinib, Dabrafenib and trametinib, Ribociclib, Lenvatinib, Pembrolizumab, Durvalumab, Rucaparib, Axitinib, Palbociclib, Crizotinib, Sunitinib, Cabozantinib, Abemaciclib, Alectinib, Atezolizumab and Bevacizumab, Ipilimumab and nivolumab, Entrectinib, Talazoparib, Dacomitinib, Lorlatinib, Erdafitinib, Alpelisib, Niraparib, Pemigatinib, Selpercatinib, Tepotinib |
| NCT03934372 Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | P1P2 | Recruiting | 70 | Open-label | Ponatinib |
| NCT05890352 Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma | P2 | Recruiting | 227 | RCT, Open-label | Lenalidomide, Tafasitamab, Tazemetostat, Zanubrutinib |
| NCT07030699 A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma | Lymphoma | P2 | Recruiting | 27 | Open-label | Epcoritamab, Lenalidomide, Tafasitamab |
| NCT07124078 A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) | Chronic Graft-versus-host-disease | P2 | Recruiting | 60 | RCT, Open-label | INCA034176, Best available Treatment (BAT) |
| NCT06616155 Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | P1P2 | Recruiting | 39 | Open-label | Enzalutamide, Ruxolitinib |
| NCT05491226 Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation | TNBC - Triple-Negative Breast Cancer, Breast Cancer | P2 | Active | 35 | Open-label | Pembrolizumab, Axatilimab |
| NCT05287113 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | Head and Neck Cancer | P2 | Active | 176 | RCT, Double-blind | Retifanlimab, INCAGN02385, INCAGN02390, Placebo |
| NCT05345002 All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | Glioma, IDH Mutation | P2 | Recruiting | 55 | Open-label | Retifanlimab, All-trans retinoic acid |
| NCT06936566 MAGIC Ruxolitinib for aGVHD | Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation | P2 | Recruiting | 98 | RCT, Open-label | Ruxolitinib, Methylprednisolone |
| NCT03610971 Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors | Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase | P2 | Active | 24 | Open-label | Ruxolitinib, BCR-ABL Tyrosine Kinase Inhibitor (TKI) |
| NCT03674047 Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) | Other Cancer | P2 | Active | 50 | Open-label | ruxolitinib |
| NCT07213973 Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | P2 | Recruiting | 40 | Open-label | Povorcitinib |
| NCT06056895 Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | P2 | Active | 12 | Open-label | Retifanlimab, Tuparstobart, Verzistobart |
| NCT05222555 Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients | Diffuse Large B Cell Lymphoma | P1P2 | Active | 53 | Open-label | Tafasitamab, Lenalidomide |
| NCT06160791 Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) | Hemophagocytic Lymphohistiocytoses | P2 | Recruiting | 36 | Open-label | Ruxolitinib, Etoposide, Dexamethasone |
| NCT04414514 Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment | Hidradenitis Suppurativa | P2 | Recruiting | 24 | Open-label | Ruxolitinib 1.5% Cream |
| NCT04225039 Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | Glioblastoma | P2 | Active | 39 | Open-label | INCMGA00012, INCAGN01876, SRS |
| NCT05351593 Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | CNS Lymphoma, Primary Central Nervous System Lymphoma | P1P2 | Recruiting | 35 | Open-label | Tafasitamab, Lenalidomide |
| NCT05177133 Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) | Gastric Adenocarcinoma, Esophageal Adenocarcinoma | P2 | Recruiting | 25 | Open-label | Capecitabine, Oxaliplatin, Retifanlimab |
| NCT04640025 A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib | Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans) | P2 | Active | 18 | Open-label | itacitinib |
| NCT04438824 Palbociclib and INCMGA00012 in People With Advanced Liposarcoma | Well-differentiated/Dedifferentiated Liposarcoma | P2 | Active | 42 | Open-label | INCMGA00012, Palbociclib |
| NCT06399029 Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities | Exanthema, Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy | P2 | Recruiting | 20 | Open-label | Ruxolitinib Topical Cream |
| NCT02928978 Ruxolitinib for Premalignant Breast Disease | Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia | P2 | Active | 100 | RCT, Double-blind | Ruxolitinib, Placebo (for Ruxolitinib) |
| NCT06388564 A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | Chronic Graft-versus-host-disease | P2 | Recruiting | 120 | RCT, Open-label | Axatilimab, Ruxolitinib, Corticosteroids |
| NCT05879822 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Advanced Solid Tumor | P2 | Active | 73 | RCT, Open-label | INCB099280 |
| NCT03954236 Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease | Non-sclerotic Cutaneous Chronic Graft-versus-host Disease | P2 | Active | 24 | Open-label | topical ruxolitinib 1.5% cream |
| NCT07126236 Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma | Large B Cell Lymphoma | P2 | Recruiting | 80 | Open-label | Epcoritamab, Epcoritamab, tafasitamab and lenalidomide |
| NCT06873789 A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | Solid Tumors, Advanced Solid Tumors | P1P2 | Active | 9 | Open-label | INCB177054, Retifanlimab |
| NCT02955940 An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | Pancreatic Cancer, Colorectal Cancer (CRC) | P2 | Active | 10 | Open-label | Ruxolitinib, Capecitabine, Regorafenib |
| NCT04061421 Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) | MDS/MPN | P1P2 | Recruiting | 94 | Open-label | ASTX727, Itacitinib, Ruxolitinib |
| NCT04859946 Itacitinib for the Prevention of Graft Versus Host Disease | Hematologic and Lymphocytic Disorder | P2 | Active | 31 | Open-label | Busulfan, Cyclophosphamide, Fludarabine, Itacitinib, Tacrolimus, Thiotepa |
| NCT07023627 A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Ovarian Cancer | P2 | Recruiting | 160 | Open-label | INCB123667 |
| NCT07085039 Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease | Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease | P2 | Recruiting | 14 | Open-label | Ruxolitinib |
| NCT06523556 Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia | Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | P1P2 | Recruiting | 52 | Open-label | Axatilimab, Azacitidine |
| NCT05453500 Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | P2 | Recruiting | 30 | Open-label | Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, Rituximab, Tafasitamab, Vincristine |
| NCT04968106 Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) | Resectable Sarcoma | P2 | Recruiting | 66 | RCT, Open-label | Doxorubicin, Ifosfamide, INCMGA00012 |
| NCT07359859 A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant | Hematologic Malignancies | P2 | Recruiting | 40 | RCT, Open-label | Cyclophosphamide, Cyclophosphamide, Mycophenolate Mofetil, Ruxolitinib, Tacrolimus, Tacrolimus |
| NCT05090891 To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | Fibrodysplasia Ossificans Progressiva (FOP) | P2 | Recruiting | 98 | RCT, Double-blind | INCB000928, Placebo |
| NCT07356245 Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | T-cell Lymphoma, Graft Versus Host Disease | P2 | Recruiting | 44 | Open-label | Ruxolitinib |
| NCT04659616 Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | Acute Myeloid Leukemia | P1 | Recruiting | 32 | Open-label | Cytarabine, Daunorubicin, Pemigatinib |
| NCT05823571 Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | Leukemia, Acute, Myelodysplastic Syndromes | P1 | Active | 32 | Open-label | Itacitinib |
| NCT02494882 Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older | Acute Lymphoblastic Leukemia | P1 | Active | 12 | Open-label | Ruxolitinib, Dasatinib, Dexamethasone |
| NCT01905813 Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies | B-cell Malignancies | P1 | Active | 121 | Open-label | INCB040093, INCB040093 + itacitinib |
| NCT07195916 A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | Solid Tumors, Hematologic Malignancies | P1 | Recruiting | 280 | Open-label | INCA036873 |
| NCT07441694 Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Myeloproliferative Neoplasms | P1 | Recruiting | 218 | RCT, Open-label | INCA036978, Standard disease-directed therapy |
| NCT07008118 A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Myeloproliferative Neoplasms | P1 | Recruiting | 120 | Open-label | INCA035784 |
| NCT05943496 Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia | P1 | Recruiting | 27 | Open-label | Acalabrutinib, Obinutuzumab, Tafasitamab |
| NCT06488378 Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer | Breast Cancer, PALB2-Mutated Breast Carcinoma | P1 | Recruiting | 20 | Open-label | Axatilimab, Olaparib |
| NCT06008808 Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | Graft Vs Host Disease, Graft-versus-host-disease | P1 | Recruiting | 41 | Open-label | Ruxolitinib, Abatacept |
| NCT06313593 A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | Myeloproliferative Neoplasms | P1 | Recruiting | 186 | Open-label | INCB160058, Standard disease-directed therapy |
| NCT03571321 Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, ALL, Childhood | P1 | Recruiting | 15 | Open-label | Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product |
| NCT03110822 A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | Multiple Myeloma | P1 | Recruiting | 134 | Open-label | Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone |
| NCT05836324 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Solid Tumors, Advanced Solid Tumors | P1 | Recruiting | 408 | Open-label | INCA33890, bevacizumab, FOLFIRI, FOLFOX, Cetuximab |
| NCT05714072 A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | Myelofibrosis Due to and Following Polycythemia Vera | P1 | Recruiting | 18 | Open-label | Ruxolitinib, Abemaciclib |
| NCT07448155 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants | Healthy Participants | P1 | Recruiting | 72 | Open-label | INCA033989 |
| NCT06818812 A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Solid Tumors | P1 | Active | 30 | Open-label | INCB186748, Cetuximab, GEMNabP, mFOLFIRINOX |
| NCT06909162 A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants | Healthy Participants | P1 | Recruiting | 51 | RCT, Open-label | INCB123667, itraconazole, carbamazepine |
| NCT06233110 Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD | Chronic Graft Versus Host Disease | P1 | Recruiting | 30 | Single-blind | Fostamatinib, Ruxolitinib |
| NCT06896188 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY) | Pancreatic Adenocarcinoma | P1 | Recruiting | 12 | Open-label | Retifanlimab, Chemotherapy, 9-ING-41 |
| NCT06179160 A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Solid Tumors | P1 | Recruiting | 710 | Open-label | INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX, FOLFOX, FOLFIRI, INCA33890 |
| NCT03874052 Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | P1 | Recruiting | 51 | Open-label | Azacitidine, Ruxolitinib, Venetoclax |
| NCT05743595 Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Unmethylated Glioblastoma | P1 | Active | 27 | Open-label | Personalized Neoantigen DNA vaccine, Retifanlimab |
| NCT05936359 A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Myeloproliferative Neoplasms | P1 | Recruiting | 225 | Open-label | INCA033989, Ruxolitinib |
| NCT06302621 Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | Advanced Solid Tumor, Unresectable Solid Tumor | P1 | Recruiting | 70 | Open-label | Afatinib, Pemigatinib |
| NCT06551584 Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT | Acute Myeloid Leukemia, Acute Lymphoid Leukemia | P1 | Recruiting | 24 | Open-label | ORCA-T |
| NCT06034002 A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Myeloproliferative Neoplasms | P1 | Recruiting | 230 | Open-label | INCA033989, Ruxolitinib |
| NCT05083754 Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma | Glioblastoma Multiforme | P1 | Recruiting | 50 | RCT, Open-label | Retifanlimab, Temozolomide |
| NCT04279847 Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms | Myelofibrosis, Myelodysplastic Syndrome | P1 | Active | 140 | Open-label | INCB057643, Ruxolitinib |
| NCT07049575 Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | Hidradenitis Suppurativa | P1 | Recruiting | 24 | Open-label | Ruxolitinib Cream |
| NCT05238922 Study of INCB123667 in Subjects With Advanced Solid Tumors | Solid Tumors | P1 | Recruiting | 604 | Open-label | INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant |
| NCT05919511 Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease | cGVHD | Recruiting | 1,500 | — | — | |
| NCT05943964 Virtual Rehabilitation in HCT | Hematopoietic Cell Transplant | N/A | Recruiting | 40 | Open-label | — |
| NCT04906746 Ruxolitinib for Cancer Cachexia | Stage IV Non-small Cell Lung Cancer, Cachexia | Early P1 | Active | 10 | Open-label | Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. |
| NCT06259669 Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population | Pregnancy Related, Atopic Dermatitis | Recruiting | 958 | — | Ruxolitinib Cream | |
| NCT06627335 An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis | Pregnancy Related, Atopic Dermatitis | Recruiting | 5,621 | — | Ruxolitinib Cream, TCS | |
| NCT04981795 realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL | Diffuse Large B-cell Lymphoma | Recruiting | 100 | — | Tafasitamab | |
| NCT06209606 Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma | Multiple Myeloma | Early P1 | Recruiting | 30 | Open-label | Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone |
| NCT04161248 Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | Lymphoma, B-Cell | Early P1 | Recruiting | 18 | Open-label | Venetoclax, Rituximab Injection, Rituximab SC, Gemcitabine, Dexamethasone, Cisplatin, Glofitamab, Tafasitamab |
| NCT06649201 Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation | Graft Vs Host Disease, Vulvovaginal Signs and Symptoms | Recruiting | 40 | — | — | |
| NCT06299553 Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) | DLBCL - Diffuse Large B Cell Lymphoma | Recruiting | 200 | — | — | |
| NCT03915964 A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis | Rheumatoid Arthritis | P4 | Completed | 2,663 | RCT, Open-label | Baricitinib, TNF Inhibitor |
| NCT05696392 The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. | Atopic Dermatitis | P4 | Terminated | 47 | Open-label | ruxolitinib cream |
| NCT04086745 A Study of Baricitinib in Participants With Rheumatoid Arthritis | Rheumatoid Arthritis | P4 | Completed | 1,317 | RCT, Open-label | Baricitinib, TNF Inhibitor |
| NCT02763319 A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma | P2P3 | Completed | 453 | RCT, Single-blind | Rituximab (RTX), Tafasitamab, Bendamustine (BEN) |
| NCT01243944 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | Polycythemia Vera | P3 | Completed | 222 | RCT, Open-label | ruxolitinib tablets |
| NCT03260894 Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | Renal Cell Carcinoma (RCC) | P3 | Completed | 129 | RCT, Open-label | Pembrolizumab, Epacadostat, Sunitinib, Pazopanib |
| NCT04551066 To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | Myelofibrosis, Primary Myelofibrosis | P3 | Terminated | 252 | RCT, Double-blind | parsaclisib, ruxolitinib, placebo |
| NCT03112603 A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) | Graft-versus-host Disease (GVHD) | P3 | Completed | 330 | RCT, Open-label | Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib |
| NCT06238817 A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 241 | RCT, Double-blind | Ruxolitinib Cream, Vehicle Cream |
| NCT03139604 GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease | Graft-versus-host Disease (GVHD) | P3 | Completed | 439 | RCT, Double-blind | Itacitinib, Placebo, Prednisone, Methylprednisolone |
| NCT04530344 Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | Vitiligo | P3 | Completed | 458 | RCT, Double-blind | ruxolitinib, Vehicle |
| NCT05755438 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | Prurigo | P3 | Completed | 204 | RCT, Double-blind | Ruxolitinib Cream, Vehicle Cream |
| NCT03656536 A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma | P3 | Terminated | 167 | RCT, Open-label | Pemigatinib, Gemcitabine, Cisplatin |
| NCT02117479 Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | Pancreatic Cancer | P3 | Terminated | 321 | RCT, Double-blind | Ruxolitinib, Placebo, Capecitabine |
| NCT03584516 GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | Chronic Graft-versus-host Disease | P2P3 | Terminated | 155 | RCT, Double-blind | Itacitinib, Placebo, Methylprednisolone, Prednisone |
| NCT03334396 A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 660 | RCT, Double-blind | Baricitinib, Placebo |
| NCT03374488 Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma | UC (Urothelial Cancer) | P3 | Completed | 84 | RCT, Open-label | Pembrolizumab, Epacadostat, Placebo |
| NCT03570749 A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata | Alopecia Areata | P2P3 | Completed | 764 | RCT, Double-blind | Baricitinib, Placebo |
| NCT03616964 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) | Systemic Lupus Erythematosus | P3 | Completed | 778 | RCT, Double-blind | Baricitinib, Placebo |
| NCT03843125 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | P3 | Terminated | 1,147 | RCT, Double-blind | Baricitinib, Placebo |
| NCT00952289 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial | MPN (Myeloproliferative Neoplasms) | P3 | Completed | 309 | RCT, Double-blind | Ruxolitinib, Placebo |
| NCT03428100 A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable | Atopic Dermatitis | P3 | Completed | 463 | RCT, Double-blind | Baricitinib, Placebo, Topical corticosteroid |
| NCT03733301 A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 329 | RCT, Double-blind | Baricitinib, Topical corticosteroid, Placebo |
| NCT05764161 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | Prurigo Nodularis | P3 | Completed | 190 | RCT, Double-blind | Ruxolitinib Cream, Vehicle Cream |
| NCT04377620 Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | COVID-19 | P3 | Terminated | 211 | RCT, Double-blind | Placebo, Ruxolitinib |
| NCT03559270 A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | P3 | Terminated | 374 | Open-label | Baricitinib |
| NCT03334435 A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 1,645 | RCT, Double-blind | Baricitinib, Placebo |
| NCT04057573 Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) | Non-segmental Vitiligo | P3 | Completed | 344 | RCT, Double-blind | Ruxolitinib cream, Vehicle |
| NCT03348904 Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | Lung Cancer | P3 | Terminated | 2 | RCT, Double-blind | Nivolumab, Epacadostat, Placebo, Carboplatin, Cisplatin, Gemcitabine, Paclitaxel, Pemetrexed |
| NCT05073458 Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia | Warm Autoimmune Hemolytic Anemia (wAIHA) | P3 | Terminated | 13 | RCT, Double-blind | parsaclisinib, placebo |
| NCT03745638 Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 631 | RCT, Double-blind | Ruxolitinib Cream, Vehicle Cream |
| NCT02752074 A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) | Melanoma | P3 | Completed | 706 | RCT, Double-blind | pembrolizumab + epacadostat, pembrolizumab + placebo |
| NCT05233410 Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 | Chronic Hand Eczema (CHE) | P3 | Withdrawn | — | RCT, Double-blind | Ruxolitinib cream, Vehicle |
| NCT03435081 A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 440 | RCT, Double-blind | Baricitinib, Placebo |
| NCT03616912 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | P3 | Terminated | 830 | RCT, Double-blind | Baricitinib, Placebo |
| NCT04849715 A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | Mantle Cell Lymphoma | P3 | Withdrawn | — | RCT, Double-blind | parsaclisib, rituximab, bendamustine, Placebo |
| NCT03342352 Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) | Head and Neck Cancer | P3 | Withdrawn | — | RCT, Double-blind | Nivolumab, Epacadostat, Placebo, Carboplatin, Cisplatin, Cetuximab, 5-Fluorouracil |
| NCT02119663 A Study of Ruxolitinib in Pancreatic Cancer Patients | Pancreatic Cancer | P3 | Terminated | 86 | RCT, Double-blind | Ruxolitinib, Placebo, Capecitabine |
| NCT05219864 Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 | Hand Eczema | P3 | Withdrawn | — | RCT, Double-blind | Ruxolitinib cream, Vehicle |
| NCT04551053 To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | Myelofibrosis, Primary Myelofibrosis | P3 | Terminated | 177 | RCT, Double-blind | parsaclisib, ruxolitinib, placebo |
| NCT03361865 Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) | UC (Urothelial Cancer) | P3 | Completed | 93 | RCT, Open-label | Pembrolizumab, Epacadostat, Placebo |
| NCT03358472 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | Head and Neck Cancer | P3 | Completed | 89 | RCT, Open-label | Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil |
| NCT04052425 Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) | Non-segmental Vitiligo | P3 | Completed | 330 | RCT, Double-blind | Ruxolitinib cream, Vehicle |
| NCT03334422 Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 615 | RCT, Double-blind | Baricitinib, Placebo |
| NCT05620836 A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | Hidradenitis Suppurativa (HS) | P3 | Completed | 619 | RCT, Double-blind | Povorcitinib, Placebo |
| NCT04362137 Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm | Cytokine Storm (Covid-19) | P3 | Completed | 432 | RCT, Double-blind | Ruxolitinib, Placebo |
| NCT04921969 A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) | Atopic Dermatitis | P3 | Completed | 330 | RCT, Double-blind | Ruxolitinib, Vehicle Cream |
| NCT04472429 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | Squamous Cell Carcinoma of the Anal Canal | P3 | Completed | 308 | RCT, Double-blind | carboplatin, paclitaxel, retifanlimab |
| NCT03745651 TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 618 | RCT, Double-blind | Ruxolitinib cream, Vehicle cream |
| NCT05456529 Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis | Atopic Dermatitis (AD) | P3 | Completed | 103 | Open-label | Ruxolitinib Cream |
| NCT04203511 INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) | Non-small Cell Lung Cancer | P3 | Withdrawn | — | RCT, Double-blind | Retifanlimab, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Etoposide |
| NCT05620823 A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | P3 | Completed | 608 | RCT, Double-blind | Povorcitinib, Placebo |
| NCT01632904 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | Polycythemia Vera | P3 | Completed | 110 | RCT, Double-blind | Ruxolitinib, Hydroxyurea (HU), HU-placebo, Ruxolitinib-placebo |
| NCT04796922 To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) | P3 | Withdrawn | — | RCT, Double-blind | parsaclisib, rituximab, obinutuzumab |
| NCT03899259 A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata | Alopecia Areata | P3 | Completed | 546 | RCT, Double-blind | Baricitinib, Placebo |
| NCT01490632 A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis | Psoriasis, Skin Diseases | P2 | Completed | 271 | RCT, Double-blind | Placebo, Baricitinib |
| NCT04055844 Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia | P2 | Completed | 14 | Open-label | Decitabine, Ruxolitinib, Donor Lymphocyte Infusion (DLI) |
| NCT03822117 Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | Solid Tumor Malignancy | P2 | Terminated | 111 | Open-label | Pemigatinib |
| NCT03721965 Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects | Acute Graft-versus-host Disease | P1P2 | Terminated | 2 | Open-label | Itacitinib, Corticosteroids |
| NCT03532295 Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas | Glioma, Glioblastoma | P2 | Completed | 51 | Open-label | Epacadostat, Bevacizumab, Retifanlimab |
| NCT04071366 A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy | Cytokine Release Syndrome | P2 | Completed | 112 | RCT, Double-blind | Itacitinib, Immune effector cell therapy, Placebo, Yescarta |
| NCT05293717 Topical Ruxolitinib in Chronic Hand Dermatitis | Chronic Hand Dermatitis | P1P2 | Completed | 16 | Open-label | Ruxolitinib |
| NCT04839380 The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 49 | Open-label | ruxolitinib cream |
| NCT02318277 A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) | Solid Tumors, Head and Neck Cancer | P1P2 | Completed | 176 | Open-label | MEDI4736, INCB024360 |
| NCT04231864 Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer | Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma | P2 | Withdrawn | — | Open-label | Durvalumab, Epacadostat |
| NCT05660421 Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors | Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | P2 | Withdrawn | — | Open-label | Itacitinib, Corticosteroid |
| NCT05359692 INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies | P2 | Withdrawn | — | Open-label | INCAGN01876, retifanlimab |
| NCT02959437 Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | Solid Tumors, Advanced Malignancies | P1P2 | Terminated | 70 | Open-label | Azacitidine, Pembrolizumab, Epacadostat, INCB057643, Pembrolizumab, Epacadostat, INCB059872 |
| NCT03144674 A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) | Lymphoma | P2 | Completed | 110 | Open-label | Parsaclisib |
| NCT02119676 Study of Ruxolitinib in Colorectal Cancer Patients | CRC (Colorectal Cancer) | P2 | Terminated | 396 | RCT, Double-blind | Ruxolitinib, Regorafenib, Placebo |
| NCT00509899 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis | Myelofibrosis, Polycythemia Vera | P1P2 | Completed | 154 | Open-label | Ruxolitinib |
| NCT02393248 Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Lung Cancer, Solid Tumor | P1P2 | Terminated | 201 | Open-label | Pemigatinib, Gemcitabine, Pembrolizumab, Docetaxel, Trastuzumab, Retifanlimab, Cisplatin |
| NCT03599713 A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) | Metastatic Merkel Cell Carcinoma | P2 | Completed | 107 | Open-label | Retifanlimab |
| NCT00617994 Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis | Psoriasis | P2 | Completed | 25 | Open-label | Ruxolitinib |
| NCT02265510 An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | Solid Tumors, Advanced Malignancies | P1P2 | Terminated | 83 | Open-label | INCB052793, gemcitabine, nab-paclitaxel, dexamethasone, Carfilzomib, bortezomib, lenalidomide, azacitidine, INCB052793, pomalidomide, INCB050465, INCB039110 |
| NCT00550043 A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 50 | RCT, Double-blind | INCB018424, Placebo |
| NCT01776723 A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib | Myelomonocytic Leukemia | P1P2 | Completed | 50 | Open-label | Ruxolitinib |
| NCT02575807 Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer | Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer | P1P2 | Terminated | 35 | RCT, Open-label | CRS-207, Epacadostat, Pembrolizumab |
| NCT02456675 INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma | Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma | P2 | Terminated | 8 | Open-label | INCB040093 Monotherapy, INCB040093, itacitinib |
| NCT03322566 A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | Lung Cancer | P2 | Completed | 233 | RCT, Double-blind | Pembrolizumab, Epacadostat, Platinum-based chemotherapy, Placebo |
| NCT03597295 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) | Squamous Cell Carcinoma of Anal Canal | P2 | Completed | 94 | Open-label | Retifanlimab |
| NCT04807777 Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma | Advanced Cutaneous Squamous Cell Carcinoma | P2 | Terminated | 3 | Open-label | Ruxolitinib |
| NCT02553330 A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA) | Alopecia Areata | P2 | Terminated | 90 | RCT, Double-blind | Placebo Cream, Ruxolitinib Phosphate Cream |
| NCT04003610 Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | P2 | Terminated | 7 | RCT, Open-label | Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin |
| NCT02711137 Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | Solid Tumors | P1P2 | Terminated | 137 | Open-label | INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine |
| NCT03277352 INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | Advanced Malignancies, Metastatic Cancer | P1P2 | Terminated | 10 | Open-label | INCAGN01876, Epacadostat, Pembrolizumab |
| NCT04200365 A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) | Chronic Graft-versus-host-disease | P2 | Terminated | 15 | Open-label | Itacitinib |
| NCT03978637 Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation | Bronchiolitis Obliterans Syndrome | P1P2 | Terminated | 23 | RCT, Open-label | Itacitinib |
| NCT02587598 Study of INCB053914 in Subjects With Advanced Malignancies | Solid Tumors | P1P2 | Terminated | 97 | Open-label | INCB053914, I-DAC (Intermediate dose cytarabine), Azacitidine, Ruxolitinib |
| NCT04231981 Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS) | Penile Cancer | P2 | Completed | 18 | Open-label | Retifanlimab |
| NCT05936567 Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria | Urticaria, Chronic Spontaneous Urticaria | P2 | Completed | 136 | RCT, Double-blind | Povorcitinib, Placebo |
| NCT04818346 A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo | NonSegmental Vitiligo | P2 | Completed | 171 | RCT, Double-blind | INCB054707, Placebo |
| NCT01633372 An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | MPN (Myeloproliferative Neoplasms) | P2 | Completed | 87 | RCT, Open-label | itacitinib |
| NCT01375140 Ruxolitinib and Lenalidomide for Patients With Myelofibrosis | Myeloproliferative Diseases | P2 | Completed | 31 | Open-label | Ruxolitinib, Lenalidomide, Prednisone |
| NCT03314935 A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | Biliary Tract Cancer (BTC), Colorectal Cancer (CRC) | P1P2 | Completed | 149 | Open-label | INCB001158, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, Cisplatin, Paclitaxel |
| NCT05906628 Topical Ruxolitinib Evaluation in Chronic Hand Eczema | Hand Eczema | P2 | Completed | 186 | RCT, Double-blind | Ruxolitinib cream, Vehicle |
| NCT02953678 A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) | Graft-versus-host Disease (GVHD) | P2 | Completed | 71 | Open-label | Ruxolitinib, Prednisone or methylprednisolone |
| NCT02917993 An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | Lung Cancer | P1P2 | Completed | 59 | Open-label | Itacitinib, Osimertinib |
| NCT01604889 A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | Melanoma | P1P2 | Terminated | 136 | RCT, Double-blind | Epacadostat, Placebo, ipilimumab, ipilimumab |
| NCT03807479 Study in Patients With Chronic Leukemia | Leukemia, Myeloid, Chronic-Phase | P2 | Terminated | 18 | Open-label | Ponatinib |
| NCT03099304 A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | Vitiligo | P2 | Completed | 157 | RCT, Double-blind | Ruxolitinib cream, Vehicle cream |
| NCT04003623 Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) | Advanced or Metastatic Solid Tumors, FGFR Mutations | P2 | Terminated | 1 | Open-label | Pemigatinib |
| NCT03627052 A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis | Moderate to Severe Ulcerative Colitis | P2 | Withdrawn | — | RCT, Double-blind | Itacitinib, Placebo |
| NCT03679767 A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer | P2 | Completed | 121 | Open-label | Retifanlimab |
| NCT02178722 Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer | P1P2 | Completed | 444 | Open-label | MK-3475, INCB024360 |
| NCT03627065 A Study of INCB050465 in Primary Sjögren's Syndrome | Primary Sjögren's Syndrome | P2 | Completed | 10 | Open-label | Parsaclisib |
| NCT03773107 LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | Multiple Myeloma | P1P2 | Completed | 12 | Open-label | Carfilzomib, Ruxolitinib, Dexamethasone |
| NCT03011372 A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) | MPN (Myeloproliferative Neoplasms) | P2 | Completed | 47 | Open-label | Pemigatinib |
| NCT01254136 Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer | Breast Cancer | P1P2 | Terminated | 20 | Open-label | INCB007839 300mg BID, Trastuzumab, Vinorelbine |
| NCT02166905 DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | Fallopian Tube Carcinoma, Ovarian Carcinoma | P1P2 | Completed | 40 | RCT, Open-label | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Epacadostat, Poly ICLC |
| NCT00393120 Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients | HIV Infections | P2 | Completed | 45 | RCT, Double-blind | INCB009471, INCB009471, Placebo comparator |
| NCT02924376 Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | Cholangiocarcinoma | P2 | Completed | 147 | Open-label | Pemigatinib |
| NCT01685255 A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | Ovarian Cancer, Genitourinary (GU) Tumors | P2 | Terminated | 83 | RCT, Open-label | Epacadostat, tamoxifen |
| NCT01961115 Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | Mucosal Melanoma, Recurrent Melanoma | P2 | Completed | 11 | Open-label | Epacadostat, MELITAC 12.1 Peptide Vaccine |
| NCT03607487 A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa | Hidradenitis Suppurativa | P2 | Completed | 35 | RCT, Double-blind | INCB054707, Placebo |
| NCT07434843 PH 2 Pemigatinib in SDH-deficient GIST | SDH Gene Mutation, Gastrointestinal Stromal Tumor | P2 | Not Yet Recruiting | 24 | Open-label | Pemigatinib |
| NCT01423604 Study of Ruxolitinib in Pancreatic Cancer Patients | Pancreatic Cancer | P2 | Completed | 136 | RCT, Double-blind | Capecitabine, Ruxolitinib, Placebo |
| NCT03006302 Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer | Metastatic Pancreatic Adenocarcinoma | P2 | Completed | 41 | Open-label | Epacadostat, Pembrolizumab, CRS-207, Cyclophosphamide, GVAX Pancreas Vaccine |
| NCT02718300 A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | MPN (Myeloproliferative Neoplasms) | P2 | Terminated | 74 | RCT, Open-label | Parsaclisib, Parsaclisib, Ruxolitinib, Parsaclisib, Parsaclisib |
| NCT00820950 A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis | Psoriasis | P2 | Completed | 29 | RCT, Double-blind | Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream, Ruxolitinib phosphate cream, Ruxolitinib phosphate cream |
| NCT03569371 A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa | Hidradenitis Suppurativa | P2 | Completed | 10 | Open-label | INCB054707 |
| NCT01348490 Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) | MPN (Myeloproliferative Neoplasms) | P2 | Completed | 66 | Open-label | Ruxolitinib |
| NCT02923349 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | Advanced Malignancies, Metastatic Cancer | P1P2 | Completed | 87 | Open-label | INCAGN01949 |
| NCT05061693 A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | Prurigo Nodularis | P2 | Completed | 146 | RCT, Double-blind | INCB054707, Placebo |
| NCT05216120 Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas | Pancreas Cancer | P2 | Withdrawn | — | Open-label | Pemigatinib 4.5 MG |
| NCT02151474 INCB047986 in Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Terminated | 3 | RCT, Double-blind | INCB047986, Placebo |
| NCT04116073 INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer | Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic | P2 | Completed | 25 | Open-label | INCMGA00012 (PD-1 antibody) |
| NCT03538041 A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia | Autoimmune Hemolytic Anemia | P2 | Completed | 25 | Open-label | Parsaclisib |
| NCT01445769 Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis | Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | P2 | Completed | 45 | Open-label | Ruxolitinib |
| NCT00726232 Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia | Myeloproliferative Neoplasm (MPN) | P2 | Terminated | 73 | RCT, Open-label | Ruxolitinib |
| NCT03126019 A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma | Lymphoma | P2 | Completed | 126 | Open-label | Parsaclisib |
| NCT03322540 Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | Lung Cancer | P2 | Completed | 154 | RCT, Double-blind | Pembrolizumab, Epacadostat, Placebo |
| NCT03361228 A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Solid Tumors | P1P2 | Terminated | 5 | Open-label | INCB001158, Epacadostat, Pembrolizumab |
| NCT05267106 Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations | Glioblastoma, Adult-type Diffuse Gliomas | P2 | Terminated | 83 | Open-label | Pemigatinib |
| NCT05127421 Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement | Atopic Dermatitis | P2 | Completed | 77 | RCT, Double-blind | Ruxolitinib cream, Vehicle |
| NCT03823131 Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | P2 | Terminated | 14 | Open-label | Epacadostat, Pembrolizumab, CORVax, Tavokinogene telseplasmid |
| NCT05593432 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus | Cutaneous Lichen Planus | P2 | Completed | 64 | RCT, Double-blind | Ruxolitinib cream, Vehicle cream |
| NCT02872714 A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | UC (Urothelial Cancer) | P2 | Completed | 263 | RCT, Open-label | pemigatinib, pemigatinib |
| NCT03837509 INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Multiple Myeloma | P1P2 | Terminated | 15 | RCT, Open-label | INCB001158, Daratumumab SC |
| NCT05593445 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus | Lichen Sclerosus | P2 | Completed | 61 | RCT, Double-blind | Ruxolitinib cream, Vehicle cream |
| NCT04582539 To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma | Myelodysplastic Syndromes, Multiple Myeloma | P1P2 | Terminated | 22 | Open-label | INCB000928 |
| NCT02119650 Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer | NSCLC (Non-small Cell Lung Carcinoma) | P2 | Terminated | 76 | RCT, Double-blind | Ruxolitinib, Placebo, Pemetrexed, Cisplatin |
| NCT02785250 Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer | P1P2 | Unknown | 85 | RCT, Open-label | Cyclophosphamide, Epacadostat (INCB024360) |
| NCT02364076 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | Thymic Carcinoma, Thymus Neoplasms | P2 | Unknown | 45 | Open-label | Pembrolizumab, Epacadostat |
| NCT03085914 A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | Solid Tumor | P1P2 | Completed | 70 | Open-label | Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Carboplatin, Cisplatin, 5-Fluorouracil, Investigator's choice of platinum agent |
| NCT04434937 Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) | Lymphoma | P2 | Completed | 42 | Open-label | parsaclisib |
| NCT01858883 Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | Solid Tumors, Pancreatic Cancer | P1P2 | Completed | 55 | Open-label | itacitinib, Gemcitabine, nab-paclitaxel, filgrastim |
| NCT02327078 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | B-cell Malignancies, Colorectal Cancer (CRC) | P1P2 | Completed | 307 | Open-label | Nivolumab, Epacadostat, Chemotherapy |
| NCT05787860 Ruxolitinib in Seborrheic Dermatitis | Seborrheic Dermatitis | P2 | Completed | 45 | Open-label | Ruxolitinib 1.5% Cream |
| NCT05565794 Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation | P2 | Terminated | 2 | Open-label | Pemigatinib |
| NCT04446182 Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD | Chronic Graft-versus-host-disease | P2 | Terminated | 3 | Open-label | Itacitinib |
| NCT05626322 Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma | P1P2 | Terminated | 6 | RCT, Open-label | Maplirpacept, Tafasitamab, Lenalidomide |
| NCT05788289 A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma | Mantle Cell Lymphoma, MCL | P2 | Terminated | 4 | Open-label | Tafasitamab, Lenalidomide |
| NCT05635838 Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa | Hidradenitis Suppurativa | P2 | Completed | 69 | RCT, Double-blind | Ruxolitinib cream, Vehicle cream |
| NCT00478322 Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects | Diabetes Mellitus, Type 2, Obesity | P2 | Completed | 24 | RCT, Double-blind | Placebo, INCB013739 |
| NCT04629339 Study of INCB086550 in Select Solid Tumors | Non Small Cell Lung Cancer, Urothelial Cancer | P2 | Terminated | 16 | Open-label | INCB086550 |
| NCT00300573 Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs | HIV Infections, Human Immunodeficiency Virus | P2 | Terminated | 250 | RCT, Double-blind | Dexelvucitabine |
| NCT02712905 An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies | Solid Tumors and Hematologic Malignancy | P1P2 | Terminated | 116 | Open-label | INCB059872, all-trans retinoic acid (ATRA), azacitidine, nivolumab |
| NCT00674479 INCB018424 in Patients With Advanced Hematologic Malignancies | Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | P2 | Completed | 51 | Open-label | INCB018424 |
| NCT04281498 Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation | Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis | P2 | Completed | 6 | Open-label | Ruxolitinib, Enasidenib |
| NCT03123588 Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) | MPN (Myeloproliferative Neoplasms) | P2 | Terminated | 12 | RCT, Double-blind | Ruxolitinib, Anagrelide, Placebo, Placebo |
| NCT02431260 An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies | Solid Tumors and Hematologic Malignancy | P1P2 | Terminated | 69 | Open-label | INCB054329 Monotherapy |
| NCT00698789 Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes | Type 2 Diabetes | P2 | Terminated | 48 | RCT, Double-blind | INCB019602, INCB019602, INCB019602, INCB019602, INCB019602, Placebo, Metformin |
| NCT02355431 Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma) | P2 | Withdrawn | — | RCT, Double-blind | Itacitinib, erlotinib, placebo |
| NCT02723994 A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | Leukemia | P2 | Completed | 171 | Open-label | Ruxolitinib, Asparaginase Erwinia Chrysanthemi, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate |
| NCT02760485 A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Lymphoma | P1P2 | Completed | 33 | Open-label | itacitinib, ibrutinib |
| NCT07252050 Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease | Sickle Cell Disease, Hematopoetic Stem Cell Transplant | P1P2 | Not Yet Recruiting | 24 | Open-label | Ruxolitinib |
| NCT04476043 To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | Hidradenitis Suppurativa, Acne Inversa | P2 | Completed | 209 | RCT, Double-blind | INCB054707, Placebo |
| NCT03144687 A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis | MPN (Myeloproliferative Neoplasms) | P2 | Completed | 23 | Open-label | Itacitinib, Ruxolitinib |
| NCT00639002 A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma | Multiple Myeloma | P2 | Completed | 13 | Open-label | Ruxolitinib 25 mg, Dexamethasone 40 mg |
| NCT01790295 Ruxolitinib Prior to Transplant in Patients With Myelofibrosis | Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis | P2 | Terminated | 21 | Open-label | Ruxolitinib Pre- Hematopoietic cell transplantation (HCT) |
| NCT07015853 ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation | TNBC - Triple-Negative Breast Cancer, Breast Cancer | P2 | Not Yet Recruiting | 34 | Open-label | Pembrolizumab, Axatilimab |
| NCT05063110 Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB | Adults Patients Having Non Severe HLH | P2 | Completed | 35 | Open-label | Itacitinib |
| NCT00902486 INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs | Rheumatoid Arthritis | P2 | Completed | 127 | RCT, Double-blind | INCB028050, INCB028050, INCB028050, Placebo |
| NCT02998476 A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) | Lymphoma | P2 | Completed | 60 | Open-label | Parsaclisib |
| NCT03427866 Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. | Myelofibrosis | P2 | Completed | 44 | Open-label | Ruxolitinib |
| NCT05949632 A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | Advanced Solid Tumors | P1P2 | Terminated | 5 | Open-label | INCB099280, axitinib |
| NCT03153982 Ruxolitinib in Operable Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | P2 | Terminated | 16 | Open-label | Ruxolitinib |
| NCT03914794 A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | Bladder Cancer, NMIBC | P2 | Completed | 30 | Open-label | Pemigatinib |
| NCT00698230 Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics | Type 2 Diabetes | P2 | Completed | 302 | RCT, Double-blind | INCB013739, INCB013739, INCB013739, INCB013739, INCB013739, Placebo comparator matching INCB013739, Metformin |
| NCT02066532 Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | Metastatic Breast Cancer, Breast Carcinoma | P1P2 | Completed | 32 | Open-label | Ruxolitinib, Trastuzumab |
| NCT01185353 A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy | Arthritis, Rheumatoid | P2 | Completed | 301 | RCT, Double-blind | LY3009104, Placebo, Methotrexate |
| NCT02041429 Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca | Recurrent Breast Cancer, Metastatic Breast Cancer | P1P2 | Completed | 20 | Open-label | Ruxolitinib, Paclitaxel |
| NCT04896385 A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA) | Vitiligo | P2 | Completed | 60 | RCT, Double-blind | Ruxolitinib cream, Vehicle Cream |
| NCT02251821 JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | Primary Myelofibrosis, Secondary Myelofibrosis | P2 | Completed | 61 | Open-label | Busulfan, Cyclophosphamide, Fludarabine Phosphate, Melphalan, Methotrexate, Mycophenolate Mofetil, Ruxolitinib, Tacrolimus |
| NCT04629508 To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) | Myelofibrosis, Polycythemia Vera | P2 | Completed | 4 | Open-label | itacitinib |
| NCT02155465 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib | Lung Cancer | P1P2 | Completed | 22 | Open-label | Ruxolitinib, Erlotinib |
| NCT07502872 TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | P2 | Not Yet Recruiting | 30 | Open-label | Tafasitamab, Polatuzumab vedotin, Glofitamab, Obinutuzumab |
| NCT00638378 Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer | Prostate Cancer | P2 | Terminated | 22 | Open-label | Ruxolitinib |
| NCT05750823 A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo | Nonsegmental Vitiligo With Genital Involvement | P2 | Completed | 49 | Open-label | Ruxolitinib Cream |
| NCT03780166 A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris | Pemphigus Vulgaris | P2 | Withdrawn | — | Open-label | Parsaclisib |
| NCT01634087 A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis | Plaque Psoriasis | P2 | Completed | 50 | RCT, Double-blind | Itacitinib, Placebo |
| NCT02076191 Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML | Myeloproliferative Neoplasms | P1P2 | Completed | 49 | Open-label | Ruxolitinib, Decitabine |
| NCT01251965 Phase l/II Study of Ruxolitinib for Acute Leukemia | Leukemia | P1P2 | Terminated | 27 | Open-label | Ruxolitinib |
| NCT02697591 A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors | Advanced Malignancies, Metastatic Cancer | P1P2 | Completed | 100 | Open-label | INCAGN01876 |
| NCT02257619 Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | NSCLC (Non-small Cell Lung Carcinoma) | P2 | Terminated | 9 | Open-label | Itacitinib, docetaxel |
| NCT01340651 Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients | Myelofibrosis | P2 | Completed | 41 | Open-label | Ruxolitinib |
| NCT02093429 Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS) | MDS (Myelodysplastic Syndrome) | P1P2 | Terminated | 6 | RCT, Open-label | INCB047986 |
| NCT00778700 A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis | Psoriasis | P2 | Completed | 199 | RCT, Double-blind | Ruxolitinib Phosphate |
| NCT03347123 A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | Solid Tumors | P1P2 | Terminated | 11 | Open-label | Epacadostat, Nivolumab, Ipilimumab, Lirilumab |
| NCT01626573 A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 106 | RCT, Double-blind | Itacitinib, Itacitinib Placebo |
| NCT04809467 A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | P1P2 | Terminated | 54 | Open-label | tafasitamab, parsaclisib |
| NCT00864175 Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer | Breast Cancer | P1P2 | Terminated | 68 | Open-label | INCB007839, INCB007839, INCB007839, INCB007839, trastuzumab, Docetaxel |
| NCT05239182 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | P2 | Terminated | 7 | Open-label | 9-ING-41, Retifanlimab, Gemcitabine, Abraxane |
| NCT03126110 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | Advanced Malignancies, Metastatic Cancer | P1P2 | Completed | 145 | Open-label | INCAGN01876, Nivolumab, Ipilimumab |
| NCT04908280 Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus | Discoid Lupus Erythematosus | P2 | Completed | 10 | Open-label | Ruxolitinib |
| NCT02018861 A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) | B-Cell Malignancies | P1P2 | Completed | 88 | Open-label | Parsaclisib, Itacitinib, Rituximab, Ifosfamide, Carboplatin, Etoposide |
| NCT01683409 A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease | Diabetic Kidney Disease | P2 | Completed | 130 | RCT, Double-blind | Baricitinib, Placebo |
| NCT01641107 Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. | Philadelphia Positive, BCR-ABL Positive | P2 | Completed | 44 | Open-label | Ponatinib |
| NCT05253807 Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration | Non-Small Cell Lung Cancer (NSCLC) | P2 | Completed | 8 | Open-label | Pemigatinib |
| NCT04586244 An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | Urothelial Carcinoma | P2 | Terminated | 30 | RCT, Open-label | retifanlimab, epacadostat, INCAGN02385, INCAGN02390 |
| NCT04354714 Ruxolitinib to Combat COVID-19 | COVID-19 | P2 | Withdrawn | — | Open-label | Ruxolitinib |
| NCT03011892 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 307 | RCT, Double-blind | Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1.5% Cream BID, Triamcinolone 0.1% Cream BID, Vehicle Cream BID |
| NCT03235544 A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor | Lymphoma | P2 | Completed | 162 | Open-label | Parsaclisib |
| NCT03878199 Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | Essential Thrombocythemia, Myelofibrosis | P1P2 | Completed | 12 | Open-label | Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib |
| NCT05247489 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo | Vitiligo | P2 | Completed | 55 | RCT, Open-label | Ruxolitinib 1.5% cream |
| NCT04294277 Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery | Urothelial Cancer | P2 | Terminated | 2 | Open-label | Pemigatinib |
| NCT02120417 A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer | Breast Cancer | P2 | Terminated | 149 | RCT, Double-blind | Ruxolitinib, Capecitabine, Placebo |
| NCT04949191 The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. | Advanced Malignancies | P2 | Terminated | 10 | Open-label | Pemigatinib, Retifanlimab, Pembrolizumab |
| NCT04370704 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | Melanoma | P1P2 | Completed | 61 | Open-label | INCAGN02385, INCAGN02390, INCMGA00012. |
| NCT01822691 Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS) | Myelodysplastic Syndromes | P2 | Completed | 15 | Open-label | INCB024360 |
| NCT07425054 HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer | Anal Cancer, HPV-Related Carcinoma | P2 | Not Yet Recruiting | 33 | Open-label | Chemotherapy, Retifanlimab |
| NCT03241173 A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | Advanced Malignancies | P1P2 | Completed | 52 | Open-label | INCAGN01949, Nivolumab, Ipilimumab |
| NCT03182894 Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P1P2 | Withdrawn | — | Open-label | Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA) |
| NCT04242199 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | Advanced Solid Tumor, MSI-H/dMMR Tumors | P1 | Completed | 182 | Open-label | INCB099280 |
| NCT03538028 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer | P1 | Completed | 22 | Open-label | INCAGN02385 |
| NCT06039384 A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | Advanced Solid Tumors | P1 | Terminated | 6 | RCT, Open-label | INCB099280, adagrasib |
| NCT07511062 Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML | Acute Myeloid Leukemia, TP53 Gene Mutation | P1 | Not Yet Recruiting | 32 | Open-label | Decitabine, Venetoclax, Axatilimab |
| NCT04674748 To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550 | Solid Tumors | P1 | Terminated | 3 | Open-label | INCB086550 |
| NCT03920839 INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) | Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer | P1 | Withdrawn | — | Open-label | Retifanlimab, Gemcitabine, Cisplatin, Pemetrexed, Carboplatin, Paclitaxel |
| NCT05624710 A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | Renal Insufficiency, Kidney Diseases | P1 | Completed | 25 | Open-label | INCB054707 |
| NCT01247883 A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers | Healthy | P1 | Completed | 13 | RCT, Open-label | PF-04634817, PF-04634817 |
| NCT01536951 A Study of LY3009104 in Healthy Participants | Healthy Participants | P1 | Completed | 62 | RCT, Double-blind | LY3009104, Placebo, moxifloxacin |
| NCT03589651 INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | Unresectable or Metastatic Solid Tumors | P1 | Completed | 83 | Open-label | Retifanlimab, Epacadostat, INCB050465 |
| NCT06337162 Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | P1 | Withdrawn | — | Open-label | INCB099280 |
| NCT01398475 A Relative Bioavailability and Food Effect Study of New Formulations | Chronic Inflammatory Disorder, Arthritis, Rheumatoid | P1 | Completed | 15 | RCT, Open-label | LY3009104 |
| NCT06941077 A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants | Healthy Volunteers | P1 | Completed | 48 | RCT, Open-label | INCB057643 |
| NCT03272464 INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. | Melanoma | P1 | Terminated | 1 | Open-label | Trametinib, Dabrafenib, INCB039110 |
| NCT06505265 A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants | Healthy Participants | P1 | Completed | 18 | Open-label | Povorcitinib |
| NCT02614612 Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD | Graft-versus-host Disease (GVHD) | P1 | Completed | 31 | RCT, Open-label | Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids) |
| NCT07018635 A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants | Healthy Participants | P1 | Completed | 63 | Open-label | INCB161734, Itraconazole, Rifampin, Esomeprazole, Famotidine |
| NCT04272034 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | Advanced Solid Tumors, MSI-H/dMMR Tumors | P1 | Terminated | 105 | Open-label | INCB099318 |
| NCT06555081 A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants | Healthy Participants | P1 | Completed | 168 | RCT, Open-label | Ruxolitinib IR, Ruxolitinib XR |
| NCT03059823 A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | Locally Advanced Solid Tumors, Metastatic Solid Tumors | P1 | Completed | 325 | Open-label | retifanlimab |
| NCT01895842 Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | Leukemia | P1 | Completed | 31 | Open-label | Ruxolitinib |
| NCT04142554 Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer | Breast Cancer, Breast Neoplasms | P1 | Withdrawn | — | Open-label | Parsaclisib |
| NCT05034822 Study of Ruxolitinib Cream in Children With Atopic Dermatitis | Atopic Dermatitis | P1 | Completed | 29 | Open-label | Ruxolitinib cream |
| NCT02118285 Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Ovarian Cancer, Fallopian Tube Carcinoma | P1 | Completed | 2 | Open-label | Fludarabine, Cyclophosphamide, NK cells, IL-2, INCB024360 |
| NCT01195311 A Dose-escalation Study in Subjects With Advanced Malignancies | Solid Tumors and Hematologic Malignancy | P1 | Completed | 52 | Open-label | INCB024360 |
| NCT00820560 Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors | Solid Tumors and Hematologic Malignancy | P1 | Completed | 41 | RCT, Open-label | INCB007839 |
| NCT04358185 Itacitinib in Advanced Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | P1 | Unknown | 24 | Open-label | Itacitinib (INCB039110) |
| NCT01072266 A Dose-escalation Study in Subjects With Advanced Malignancies | Solid Tumor, Advanced Cancer | P1 | Completed | 45 | Open-label | INCB028060 |
| NCT05068466 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707 | Healthy Participants | P1 | Completed | 30 | RCT, Double-blind | INCB054707, Placebo |
| NCT03235570 A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) | Solid Tumors | P1 | Completed | 44 | Open-label | Pemigatinib |
| NCT05577182 Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies | Advanced Malignancies | P1 | Completed | 46 | Open-label | INCA32459-101 |
| NCT04580485 INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | Ovarian Cancer, Bladder Cancer | P1 | Completed | 54 | Open-label | INCB106385, INCMGA00012 |
| NCT04989387 Study of INCA 0186 in Subjects With Advanced Solid Tumors | Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN) | P1 | Terminated | 57 | Open-label | INCA00186, Retifanlimab, INCB106385 |
| NCT03497273 Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects | Acute Graft-versus-host Disease | P1 | Completed | 14 | Open-label | Itacitinib, Corticosteroid |
| NCT06213818 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant | Healthy Participants | P1 | Completed | 137 | RCT, Double-blind | INCB160058, Placebo, Esomeprazole, Famotidine |
| NCT06441318 A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants | Healthy Participants | P1 | Completed | 128 | RCT, Double-blind | Povorcitinib, Placebo, Moxifloxacin |
| NCT07225439 Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | P1 | Not Yet Recruiting | 15 | Open-label | Allogeneic NK cells, Rituximab, Tafasitamab, Interleukin-2, Fludarabine/cyclophosphamide |
| NCT05624723 Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis | Renal Insufficiency, Kidney Diseases | P1 | Completed | 43 | Open-label | INCB054707 |
| NCT03424122 INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | B-cell Lymphoma | P1 | Completed | 50 | Open-label | Parsaclisib, Rituximab, Bendamustine, Ibrutinib |
| NCT03257644 A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | Atopic Dermatitis | P1 | Completed | 70 | Open-label | Ruxolitinib phosphate cream |
| NCT03522142 A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies | Advanced Solid Tumors | P1 | Terminated | 83 | Open-label | INCB081776, INCMGA00012 |
| NCT06380205 A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females | Healthy Participants | P1 | Completed | 24 | Open-label | Povorcitinib, Levonorgestrel/Ethinyl estradiol |
| NCT01730248 A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis | Myelofibrosis | P1 | Terminated | 63 | Open-label | INC424, BKM120 |
| NCT04831996 To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment. | Advanced Malignancies | P1 | Completed | 48 | Open-label | parsaclisib |
| NCT03132324 A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease | Sickle Cell Disease | P1 | Terminated | 12 | Open-label | INCB059872 |
| NCT02298153 A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110) | NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer) | P1 | Terminated | 29 | Open-label | atezolizumab, epacadostat |
| NCT06775327 Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants | Healthy Participants | P1 | Completed | 71 | RCT, Double-blind | INCB000631, Placebo |
| NCT03670069 Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma | P1 | Terminated | 27 | Open-label | Itacitinib |
| NCT03910530 A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors | Advanced Solid Tumors, Metastatic Solid Tumors | P1 | Completed | 18 | Open-label | Retifanlimab, INCB001158, Retifanlimab + INCB001158 |
| NCT03039114 Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) | Lymphoma | P1 | Completed | 26 | Open-label | Parsaclisib, Hexal, Gazyvaro |
| NCT03688152 A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | P1 | Completed | 9 | Open-label | INCB053914, INCB050465 |
| NCT05440942 Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | P1 | Completed | 28 | Open-label | Trametinib, Ruxolitinib, Retifanlimab |
| NCT01702064 Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients | Chronic Phase Chronic Myeloid Leukemia | P1 | Completed | 11 | Open-label | Nilotinib, Ruxolitinib |
| NCT05099445 Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis | Renal Impairment, Hemodialysis | P1 | Completed | 48 | Open-label | INCB000928 |
| NCT03755414 Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | P1 | Completed | 55 | Open-label | Itacitinib |
| NCT06713590 A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants | Healthy Participants | P1 | Completed | 72 | RCT, Open-label | Axatilimab |
| NCT07218744 Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants | Healthy Participants | P1 | Completed | 9 | Open-label | INCB123667 |
| NCT02559492 Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors | Solid Tumors | P1 | Terminated | 142 | Open-label | Itacitinib, Epacadostat, Itacitinib, INCB050465 |
| NCT03314922 A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | Lymphoma | P1 | Completed | 17 | Open-label | Parsaclisib |
| NCT00398619 A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes | Insulin Resistance, Obesity | P1 | Completed | — | RCT, Double-blind | INCB13739 |
| NCT01822756 An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | Solid Tumors, Pancreatic Cancer | P1 | Terminated | 42 | Open-label | ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim |
| NCT05101369 A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550 | Healthy Volunteers | P1 | Completed | 7 | Open-label | INCB086550 |
| NCT03471286 A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies | Solid Tumor | P1 | Terminated | 2 | Open-label | Epacadostat |
| NCT01317875 Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) | Myelofibrosis | P1 | Completed | 69 | RCT, Open-label | Ruxolitinib |
| NCT06213831 A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream | Prurigo Nodularis | P1 | Completed | 23 | Open-label | Ruxolitinib Cream 1.5% |
| NCT03514407 A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma | Relapsed Ewing Sarcoma | P1 | Terminated | 25 | Open-label | INCB059872 |
| NCT04070781 Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease | Steroid Refractory GVHD, Graft Vs Host Disease | P1 | Terminated | 1 | RCT, Open-label | Itacitinib, Tocilizumab |
| NCT04831944 To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment. | Advanced Malignancies | P1 | Completed | 21 | Open-label | parsaclisib |
| NCT02903914 Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | Metastatic Cancer, Solid Tumors | P1 | Completed | 260 | Open-label | INCB001158, Pembrolizumab |
| NCT03144661 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | Hepatocellular Carcinoma (HCC), Cholangiocarcinoma | P1 | Terminated | 25 | Open-label | INCB062079 |
| NCT05909995 Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | Melanoma, Hepatocellular Carcinoma (HCC) | P1 | Terminated | 8 | Open-label | INCB 99280 with Ipilimumab |
| NCT02646748 Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Colorectal Cancer (CRC), Endometrial Cancer | P1 | Completed | 159 | Open-label | Pembrolizumab, itacitinib, INCB050465 |
| NCT03652077 A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | Cervical Cancer, Gastric Cancer | P1 | Completed | 40 | Open-label | INCAGN02390 |
| NCT03762447 A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors | Solid Tumors | P1 | Completed | 138 | Open-label | INCB086550 |
| NCT07424222 Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) | Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) | P1 | Not Yet Recruiting | 16 | Open-label | Ruxolitinib |
| NCT04799431 Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer | Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic | P1 | Withdrawn | — | Open-label | Neoantigen Vaccine with Poly-ICLC adjuvant, Retifanlimab |
| NCT03920852 A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis | Atopic Dermatitis | P1 | Completed | 41 | Open-label | Ruxolitinib cream |
| NCT06310304 A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants. | Healthy Participants | P1 | Completed | 24 | RCT, Open-label | Ruxolitinib IR, Ruxolitinib XR |
| NCT06416800 A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants | Healthy Participants | P1 | Completed | 71 | RCT, Open-label | Digoxin, Rosuvastatin, Metformin, Povorcitinib, Probenecid |
| NCT03320642 GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease | Hematologic Malignancies | P1 | Terminated | 84 | Open-label | Itacitinib, Calcineurin inhibitor |
| NCT06309394 A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants | Healthy Participants | P1 | Completed | 5 | Open-label | INCB099280 |
| NCT01929941 An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies | Solid Tumor, Hodgkin's Lymphoma | P1 | Terminated | 5 | Open-label | INCB047986, INCB047986, Gemcitabine, nab-paclitaxel |
| NCT07039929 Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants | Healthy Participants | P1 | Terminated | 24 | RCT, Double-blind | INCB000631, Placebo |
| NCT03906344 Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis | NO_LONGER_AVAILABLE | — | — | INCB052793 | ||
| NCT06218082 Vitiligo Registry for Adults and Children in the UK | Dermatologic Disease, Vitiligo | Not Yet Recruiting | 30 | — | — | |
| NCT05544032 Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD) | Chronic Graft Vs. Host Disease | AVAILABLE | — | — | axatilimab | |
| NCT05722912 Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD | Graft-versus-host Disease (GVHD) | APPROVED_FOR_MARKETING | — | — | Ruxolitinib | |
| NCT06934980 A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants | Atopic Dermatitis, Healthy Volunteers | Completed | 20 | — | — | |
| NCT03147742 An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant | Graft-versus-host Disease (GVHD) | APPROVED_FOR_MARKETING | — | — | Ruxolitinib | |
| NCT03647215 CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey | Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia | Completed | 427 | — | — | |
| NCT03906318 Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia | Aplastic Anemia | NO_LONGER_AVAILABLE | — | — | Iticitinib | |
| NCT03515785 A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON" | BCR-ABL Positive Acute Lymphoblastic Leukemia | Withdrawn | — | — | — | |
| NCT04355793 Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection | COVID-19 | NO_LONGER_AVAILABLE | — | — | Ruxolitinib | |
| NCT02252159 Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) | MPN (Myeloproliferative Neoplasms) | Completed | 2,544 | — | — | |
| NCT06910137 An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC) | Squamous Cell Carcinoma of the Anal Canal | AVAILABLE | — | — | retifanlimab | |
| NCT01730755 Ruxolitinib for Chuvash Polycythemia | Erythrocytosis, Familial, 2 | NO_LONGER_AVAILABLE | — | — | Ruxolitinib | |
| NCT03906357 Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer | NO_LONGER_AVAILABLE | — | — | Pemigatinib | ||
| NCT05298293 Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma | Diffuse Large B Cell Lymphoma | N/A | Not Yet Recruiting | 160 | RCT, Open-label | — |
| NCT03896815 Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma | NO_LONGER_AVAILABLE | — | — | INCB054329 | ||
| NCT02469974 Ruxolitinib in Combination With Autotransplant | Myelofibrosis, MF | N/A | Withdrawn | — | Open-label | RUXOLITINIB / INC 424, Filgrastim, Busulfan |
| NCT03678454 Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium | Chronic Myeloid Leukemia, CML | Completed | 80 | — | — | |
| NCT04048564 Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®) | Chronic Myeloid Leukemia | Completed | 120 | — | — | |
| NCT05561985 Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease | STAT1 Gain-of-Function Disease | AVAILABLE | — | — | Itacitinib | |
| NCT02953704 Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) | MPN (Myeloproliferative Neoplasms) | Completed | 1,469 | — | — |